{
    "clinical_study": {
        "@rank": "8222", 
        "arm_group": [
            {
                "arm_group_label": "PEG 3350", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG\n      3350 solution concentrate to oral ingestion of a placebo solution concentrate, in\n      participants with constipation."
        }, 
        "brief_title": "Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ambulatory male or female with no history or current evidence of other conditions or\n             abnormalities that would affect study results or interfere with participation for\n             full duration of study\n\n          -  meets diagnostic criteria for functional constipation. This includes loose stools\n             that are rarely present without the use of laxatives and 2 or more of the following:\n             straining during at least 25% of defecations; lumpy or hard stools in at least 25% of\n             defecations; sensation of incomplete evacuation for at least 25% of defecations;\n             sensation of anorectal obstruction/blockage for at least 25% of defecations; manual\n             maneuvers to facilitate at least 25% of defecations [e.g., digital evacuation,\n             support of the pelvic floor]; and fewer than 3 defecations per week. Criteria for\n             functional constipation must be fulfilled for last 3 months, with symptom onset at\n             least 6 months prior to diagnosis.\n\n          -  continuous or recurrent symptoms for at least 3 months of: abdominal pain or\n             discomfort, relieved with defecation, or associated with a change in frequency or\n             consistency of stool, and an irregular pattern of defecation at least 25% of the time\n             with 3 or more of the following: altered stool frequency, altered stool form (hard or\n             loose/watery), altered stool passage (straining or urgency, feeling of incomplete\n             evacuation), passage of mucus, and bloating or abdominal distension\n\n          -  agrees to not use laxatives other than study medication for the duration of the study\n             period\n\n          -  agrees to not use disallowed concomitant medications for the duration of the study\n\n          -  agrees to maintain a similar diet and level of activity from the period of the\n             Screening Visit through End of Study\n\n          -  individuals of reproductive potential must agree to remain abstinent or use (or have\n             their partner use) 2 acceptable methods of birth control and until 2 weeks after the\n             last dose of study drug in the last treatment period. Acceptable methods of birth\n             control include: intrauterine device (IUD), diaphragm with spermicide, contraceptive\n             sponge, condom, or vasectomy.\n\n        Exclusion Criteria:\n\n          -  abnormal baseline endoscopy and/or an oral exam\n\n          -  baseline oral exam showing evidence of oral lesions, such as herpes labialis or\n             aphthous stomatitis, or known self-reported history or current periodontal gum\n             disease\n\n          -  history of impaired swallowing or difficulties swallowing foods and liquids\n\n          -  known, history of, or suspected gastrointenstinal disease, including bowel\n             perforation, obstruction, fecal impaction; irritable bowel syndrome (IBS), delayed\n             gastric emptying, gastroparesis, gastroesophageal reflux disease (GERD), gastritis or\n             peptic ulcer disease (PUD), dehydration, inflammatory bowel disease, bowel resection,\n             anal fistulas/fissures, colostomy, etc.\n\n          -  severe or unexplained abdominal pain\n\n          -  history of or current alcohol or drug abuse\n\n          -  history of malignancy \u22645 years prior to signing the informed consent, except for\n             adequately treated basal cell and/or squamous cell skin cancer or in situ cervical\n             cancer\n\n          -  history of psychiatric illness requiring medications or hospitalization within the\n             previous 12 months\n\n          -  history of concurrent illness that required hospitalization within 4 weeks prior to\n             Day -1 of the study\n\n          -  allergies or allergic reactions or intolerance to any of the products used in study\n\n          -  any degree of renal impairment\n\n          -  major surgery or clinically significant illness within 4 weeks prior to Day -1 of\n             Visit 1\n\n          -  current  or recent (within the past 30 days of signing informed consent)\n             participation in a study with an investigational compound or device\n\n          -  refusal to agree not to donate eggs or sperm upon the first study drug administration\n             and thereafter through 90 days after the last study drug administration\n\n          -  individual is an employee or family member of an employee of the sponsor or clinical\n             unit where study will be conducted"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "67", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885104", 
            "org_study_id": "8114-003", 
            "secondary_id": "CL2012-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "PEG 3350", 
                "intervention_name": "Polyethylene Glycol (PEG 3350)", 
                "intervention_type": "Drug", 
                "other_name": "MiraLAX Solution Concentrate"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 8, 2013", 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with inflammation of the oral mucosa", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 days after start of treatment"
            }, 
            {
                "measure": "Number of participants with inflammation of the esophageal mucosa", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 17 days after start of treatment"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885104"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}